February 17, 2022
Video
The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]
February 11, 2022
Video
The chief medical officer at Atara Biotherapeutics discussed the investigational agent ATA188, its mechanism to treat multiple sclerosis, and what to look for in its upcoming EMBOLD trial data readout. [WATCH TIME: 4 minutes]
February 09, 2022
Video
The chief medical officer at Atara Biotherapeutics detailed the clinical significance of a recently published paper in Nature that adds to the evidence that Epstein-Barr virus is the leading cause of multiple sclerosis. [WATCH TIME: 3 minutes]
NeurologyLive® Brain Games: May 22, 2022
New Research Highlights Reasons, Risk Factors, and Consequences for Self-Discontinuation of Antiseizure Medication in Newly Diagnosed Epilepsy
New Drug Application Submitted for Continuous Subcutaneous Carbidopa/Levodopa Formulation
Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted